Australia's most trusted
source of pharma news
Tuesday, 01 July 2025
Posted 13 June 2025 AM
Two new therapies are set to reach Australian shores under an expanded deal between Specialised Therapeutics (ST) and Incyte Biosciences.
The expanded agreement will see CSF-1R-blocking antibody Niktimvo and PD-1 inhibitor Zynyz added to the current partnered portfolio of Minjuvi and Pemazyre.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.